Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISB 1342

Next Previous
Drug Profile

ISB 1342

Alternative Names: CD38 x CD3 BEAT® 1.0 bispecific antibody; CD38/CD3 Bispecific Antibody; GBR-1342; ISB-1342

Latest Information Update: 02 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals S.A.
  • Developer Glenmark Pharmaceuticals S.A.; Ichnos Sciences
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma
  • No development reported Solid tumours

Most Recent Events

  • 30 Jan 2024 Glenmark Pharmaceuticals S.A. plans to initiate a phase I trial for precursor-T-cell-lymphoblastic-leukaemia-lymphoma
  • 09 Dec 2023 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 13 Nov 2023 ISB 1342 is still in phase I development in Multiple-myeloma (Second-line therapy or greater) in France (IV, Infusion) (NCT03309111)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top